Liraglutide (LIR) is a novel long-lasting glucagon-like peptide-1 (GLP-1) analogue that facilitates insulin signalling and shows also neuroprotective properties in different brain disease models. In this study, we explored the potential antiepileptogenic effects of LIR in two different animal models; namely, the mouse intrahippocampal kainic acid (KA) model of temporal lobe epilepsy and the WAG/Rij rat model of absence epileptogenesis. Moreover, we evaluated LIR effects on comorbidities in various behavioural tests. Mice with kainate-induced epilepsy were treated with LIR (300 g/kg/day s.c.) for 4 weeks after status epilepticus and then evaluated for drug effects on seizure development and behavioural alterations, whereas WAG/Rij rats were ...
BACKGROUND: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cog...
Type 2 diabetes mellitus is a risk factor of Alzheimer's disease (AD), most likely linked to an impa...
The aim of the present study was to determine whether treatment with liraglutide, a glucagon-like pe...
Glucagon-like peptide-1(GLP-1) is a growth factor that has neuroprotective and anti-inflammatory pro...
Diabetes has been identified as a risk factor for cognitive dysfunctions. Glucagone like peptide 1 (...
Objectives: To study the possible anti-seizure and neuroprotective effect of glucagon like peptide 1...
Epilepsy is one of the most prevalent neurological diseases in the world and 30% of patients are ref...
Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk facto...
Dravet syndrome (DS) is a refractory epilepsy typically caused by heterozygous mutations of the Scn1...
Background/Aims: Glucagon-like peptide-1 (GLP-1)-based drugs are being used to achieve better glucos...
PurposeThis study aimed to investigate whether 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl...
Glucagon-like peptide 1 (GLP-1) is a growth factor. GLP-1 mimetics are on the market as treatments f...
The number of diabetes mellitus (DM) patients is increasing, and stroke is deeply associated with DM...
Mood disorder patients that are on long-term atypical antipsychotics treatment frequently experience...
Objective(s): Although the available therapeutic agents alleviate the symptoms in patients with temp...
BACKGROUND: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cog...
Type 2 diabetes mellitus is a risk factor of Alzheimer's disease (AD), most likely linked to an impa...
The aim of the present study was to determine whether treatment with liraglutide, a glucagon-like pe...
Glucagon-like peptide-1(GLP-1) is a growth factor that has neuroprotective and anti-inflammatory pro...
Diabetes has been identified as a risk factor for cognitive dysfunctions. Glucagone like peptide 1 (...
Objectives: To study the possible anti-seizure and neuroprotective effect of glucagon like peptide 1...
Epilepsy is one of the most prevalent neurological diseases in the world and 30% of patients are ref...
Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk facto...
Dravet syndrome (DS) is a refractory epilepsy typically caused by heterozygous mutations of the Scn1...
Background/Aims: Glucagon-like peptide-1 (GLP-1)-based drugs are being used to achieve better glucos...
PurposeThis study aimed to investigate whether 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl...
Glucagon-like peptide 1 (GLP-1) is a growth factor. GLP-1 mimetics are on the market as treatments f...
The number of diabetes mellitus (DM) patients is increasing, and stroke is deeply associated with DM...
Mood disorder patients that are on long-term atypical antipsychotics treatment frequently experience...
Objective(s): Although the available therapeutic agents alleviate the symptoms in patients with temp...
BACKGROUND: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cog...
Type 2 diabetes mellitus is a risk factor of Alzheimer's disease (AD), most likely linked to an impa...
The aim of the present study was to determine whether treatment with liraglutide, a glucagon-like pe...